[
  {
    "ts": null,
    "headline": "These Stocks Lead Dow Jones In February. Hint: It's Not AI Companies.",
    "summary": "As technology, financial and consumer discretionary sectors struggle this year, investors have shifted to an odd mix of economically sensitive sectors such as materials and energy along with consumer staples and utilities.",
    "url": "https://finnhub.io/api/news?id=b18fd21b9bdc7ea889600e4951d6f264ac8cdc50627913010127519864b6cbb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772227839,
      "headline": "These Stocks Lead Dow Jones In February. Hint: It's Not AI Companies.",
      "id": 139256962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "As technology, financial and consumer discretionary sectors struggle this year, investors have shifted to an odd mix of economically sensitive sectors such as materials and energy along with consumer staples and utilities.",
      "url": "https://finnhub.io/api/news?id=b18fd21b9bdc7ea889600e4951d6f264ac8cdc50627913010127519864b6cbb7"
    }
  },
  {
    "ts": null,
    "headline": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
    "summary": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
    "url": "https://finnhub.io/api/news?id=fd445e2724625e6a109ff734f0648892f87df7df2e8e983c77c57a0bb579559e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772209080,
      "headline": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
      "id": 139256613,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=fd445e2724625e6a109ff734f0648892f87df7df2e8e983c77c57a0bb579559e"
    }
  },
  {
    "ts": null,
    "headline": "J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?",
    "summary": "JNJ stock has surged 38% in six months on strong drug and MedTech growth, but patent losses and lawsuits loom. Is it still a hold?",
    "url": "https://finnhub.io/api/news?id=79194f401a07c69459eb663fb15611eaa232cc7b5995bf3e2e32dd588470ffc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772204520,
      "headline": "J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?",
      "id": 139254344,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ stock has surged 38% in six months on strong drug and MedTech growth, but patent losses and lawsuits loom. Is it still a hold?",
      "url": "https://finnhub.io/api/news?id=79194f401a07c69459eb663fb15611eaa232cc7b5995bf3e2e32dd588470ffc4"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For March 2026",
    "summary": "NOBL is up 9.39% YTD vs SPYâs 1.08% as Dividend Aristocrats rebound in 2026.",
    "url": "https://finnhub.io/api/news?id=c0fc60f021ba8668f89aa3a46f7b3fd9afaf3313c8e3b9b8155c6a4d110db360",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772194865,
      "headline": "Best Dividend Aristocrats For March 2026",
      "id": 139252799,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "NOBL is up 9.39% YTD vs SPYâs 1.08% as Dividend Aristocrats rebound in 2026.",
      "url": "https://finnhub.io/api/news?id=c0fc60f021ba8668f89aa3a46f7b3fd9afaf3313c8e3b9b8155c6a4d110db360"
    }
  },
  {
    "ts": null,
    "headline": "2 Reasons I'd Happily Hold Johnson & Johnson Through Any Market Crash",
    "summary": "The company has proven its resilience in the past.",
    "url": "https://finnhub.io/api/news?id=ca7b0d2fa4e5cabdded257d20ccf451552ea33c9d3224bdca1d40cb81f407e93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772191560,
      "headline": "2 Reasons I'd Happily Hold Johnson & Johnson Through Any Market Crash",
      "id": 139245903,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The company has proven its resilience in the past.",
      "url": "https://finnhub.io/api/news?id=ca7b0d2fa4e5cabdded257d20ccf451552ea33c9d3224bdca1d40cb81f407e93"
    }
  },
  {
    "ts": null,
    "headline": "Why You May Have To Rethink Your Retirement Strategy (I Sure Did)",
    "summary": "Why You May Have To Rethink Your Retirement Strategy (I Sure Did)",
    "url": "https://finnhub.io/api/news?id=6a2480aef7d93be2bd25b6758e28a878b35487aa960f75a9885fd3baf78eec44",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772177400,
      "headline": "Why You May Have To Rethink Your Retirement Strategy (I Sure Did)",
      "id": 139246264,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6a2480aef7d93be2bd25b6758e28a878b35487aa960f75a9885fd3baf78eec44"
    }
  },
  {
    "ts": null,
    "headline": "Johnson And Johnson Faces Fresh Talc Verdict As Pipeline Story Evolves",
    "summary": "Philadelphia jury orders Johnson & Johnson to pay damages in a talc related ovarian cancer case, the first plaintiff win there since litigation restarted. Verdict comes after prior bankruptcy efforts to contain tens of thousands of talc lawsuits were halted, putting fresh focus on product liability risk. Bayer files a separate lawsuit over Johnson & Johnson prostate cancer drug marketing practices. Company reports recent R&D milestones in oncology and autoimmune disease treatments. For...",
    "url": "https://finnhub.io/api/news?id=2ff77550b02588211229b88180380cc53035b68e853f7478cb1a8d74db28bf72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772152173,
      "headline": "Johnson And Johnson Faces Fresh Talc Verdict As Pipeline Story Evolves",
      "id": 139241885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Philadelphia jury orders Johnson & Johnson to pay damages in a talc related ovarian cancer case, the first plaintiff win there since litigation restarted. Verdict comes after prior bankruptcy efforts to contain tens of thousands of talc lawsuits were halted, putting fresh focus on product liability risk. Bayer files a separate lawsuit over Johnson & Johnson prostate cancer drug marketing practices. Company reports recent R&D milestones in oncology and autoimmune disease treatments. For...",
      "url": "https://finnhub.io/api/news?id=2ff77550b02588211229b88180380cc53035b68e853f7478cb1a8d74db28bf72"
    }
  }
]